US2677682A
(en)
|
1951-08-24 |
1954-05-04 |
American Cyanamid Co |
Sulfonamido pteridines
|
ID18983A
(id)
|
1996-12-04 |
1998-05-28 |
Lilly Co Eli |
Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
|
SE0001899D0
(sv)
|
2000-05-22 |
2000-05-22 |
Pharmacia & Upjohn Ab |
New compounds
|
US8933236B2
(en)
|
2012-05-22 |
2015-01-13 |
Xenon Pharmaceuticals Inc. |
N-substituted benzamides and methods of use thereof
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
CN1612866A
(zh)
|
2001-11-14 |
2005-05-04 |
特瓦制药工业有限公司 |
无定形和结晶形的氯沙坦钾及其制备方法
|
CN101675928A
(zh)
|
2003-11-14 |
2010-03-24 |
沃泰克斯药物股份有限公司 |
可用作atp-结合弹夹转运蛋白调控剂的噻唑和噁唑
|
AU2005210474B2
(en)
|
2004-01-30 |
2011-07-07 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding cassette transporters
|
PL1773816T3
(pl)
|
2004-06-24 |
2015-06-30 |
Vertex Pharma |
Modulatory transporterów posiadających kasetę wiążącą ATP
|
US8354427B2
(en)
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
NZ566208A
(en)
|
2005-08-11 |
2010-09-30 |
Vertex Pharma |
2-Thiazolamide derivatives as modulators of cystic fibrosis transmembrane conductance regulators
|
WO2007053641A2
(en)
|
2005-11-01 |
2007-05-10 |
Mars, Incorporated |
A-type procyanidins and inflammation
|
EP3208272B1
(en)
|
2005-11-08 |
2020-01-08 |
Vertex Pharmaceuticals Incorporated |
Heterocyclic modulators of atp-binding cassette transporters
|
CA2635214A1
(en)
|
2005-12-27 |
2007-07-05 |
Vertex Pharmaceuticals Incorporated |
Compounds useful in cftr assays and methods therewith
|
US7671221B2
(en)
|
2005-12-28 |
2010-03-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
HUE049976T2
(hu)
|
2005-12-28 |
2020-11-30 |
Vertex Pharma |
N-[2,4-bisz(1,1-dimetil-etil)-5-hidroxi-fenil]-1,4-dihidro-4-oxo-kinolin-3-karboxamid amorf alakjának gyógyászati kompozíciói
|
EP2016065B1
(en)
|
2005-12-28 |
2012-09-19 |
Vertex Pharmaceuticals Incorporated |
1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis
|
PL3327016T3
(pl)
|
2006-04-07 |
2021-10-04 |
Vertex Pharmaceuticals Incorporated |
Wytwarzanie modulatorów transporterów posiadających kasetę wiążącą ATP
|
EP2021797B1
(en)
|
2006-05-12 |
2011-11-23 |
Vertex Pharmaceuticals, Inc. |
Compositions of n-ý2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl¨-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
CN101715450B
(zh)
|
2006-11-03 |
2013-03-13 |
沃泰克斯药物股份有限公司 |
作为cftr调控剂的氮杂吲哚衍生物
|
EP2167491A1
(en)
|
2007-06-08 |
2010-03-31 |
Abbott Laboratories |
5-heteroaryl substituted indazoles as kinase inhibitors
|
US8163772B2
(en)
|
2007-09-14 |
2012-04-24 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxypheny1]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
EA201070700A1
(ru)
|
2007-12-07 |
2011-06-30 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способы получения циклоалкилкарбоксамидопиридинбензойных кислот
|
RS55559B1
(sr)
|
2007-12-07 |
2017-05-31 |
Vertex Pharma |
Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il) benzoeve kiseline
|
JP5523352B2
(ja)
|
2008-02-28 |
2014-06-18 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Cftr修飾因子としてのへテロアリール誘導体
|
NO2328618T3
(es)
|
2008-08-13 |
2018-04-28 |
|
|
MX2011003249A
(es)
|
2008-09-29 |
2011-05-19 |
Vertex Pharma |
Unidades de dosificacion del acido 3-(6-(1-(2,2-difluorobenzo[d][1 ,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoi co.
|
BRPI0919930A2
(pt)
|
2008-10-23 |
2016-02-16 |
Vertex Pharma |
moduladores de regulador de condutância transmembrana de fibrose cística
|
SI2365972T1
(sl)
|
2008-11-06 |
2015-04-30 |
Vertex Pharmaceuticals Incorporated |
Modulatorji prenaĺ alcev z atp-vezavno kaseto
|
UA104876C2
(uk)
|
2008-11-06 |
2014-03-25 |
Вертекс Фармасьютікалз Інкорпорейтед |
Модулятори atф-зв'язувальних касетних транспортерів
|
KR101852173B1
(ko)
|
2009-03-20 |
2018-04-27 |
버텍스 파마슈티칼스 인코포레이티드 |
낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
|
AU2010289326B2
(en)
|
2009-09-04 |
2015-09-24 |
Horizon Therapeutics U.S. Holding Llc |
Use of aerosolized levofloxacin for treating cystic fibrosis
|
CN102665715A
(zh)
|
2009-10-22 |
2012-09-12 |
沃泰克斯药物股份有限公司 |
治疗囊性纤维化和其他慢性疾病的组合物
|
EP2547658A1
(en)
|
2010-03-19 |
2013-01-23 |
Vertex Pharmaceuticals Incorporated |
Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
CN109081804B
(zh)
|
2010-03-25 |
2021-12-10 |
弗特克斯药品有限公司 |
环丙烷甲酰胺的固体形式
|
NZ602838A
(en)
|
2010-04-07 |
2015-06-26 |
Vertex Pharma |
Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof
|
CN102933206A
(zh)
|
2010-04-07 |
2013-02-13 |
弗特克斯药品有限公司 |
3-(6-(1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙烷甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的固体形式
|
US9504623B2
(en)
|
2010-04-09 |
2016-11-29 |
Ekso Bionics, Inc. |
Exoskeleton load handling system and method of use
|
WO2011133951A1
(en)
|
2010-04-22 |
2011-10-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
KR101984225B1
(ko)
|
2010-04-22 |
2019-05-30 |
버텍스 파마슈티칼스 인코포레이티드 |
시클로알킬카르복스아미도-인돌 화합물의 제조 방법
|
US8563593B2
(en)
|
2010-06-08 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
|
WO2012027247A2
(en)
|
2010-08-23 |
2012-03-01 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
|
NZ607494A
(en)
|
2010-08-27 |
2015-04-24 |
Vertex Pharma |
Pharmaceutical composition and administrations thereof
|
WO2012093773A2
(ko)
|
2011-01-04 |
2012-07-12 |
에이큐 주식회사 |
광고 정보 제공 시스템
|
ME03652B
(me)
|
2011-05-18 |
2020-07-20 |
Vertex Pharmaceuticals Europe Ltd |
Deuterisani derivati ivakaftora
|
HUE047354T2
(hu)
|
2011-05-18 |
2020-04-28 |
Vertex Pharmaceuticals Europe Ltd |
Ivacaftor deuterizált származékai
|
JP5886433B2
(ja)
|
2011-09-16 |
2016-03-16 |
ノバルティス アーゲー |
嚢胞性線維症処置のためのヘテロ環式化合物
|
EP2773641B1
(en)
|
2011-10-31 |
2017-09-27 |
Xenon Pharmaceuticals Inc. |
Biaryl ether sulfonamides and their use as therapeutic agents
|
ME02650B
(me)
|
2011-11-08 |
2017-06-20 |
Vertex Pharma |
Modulatori atp- vezujućih kasetnih transportera
|
UA114619C2
(uk)
|
2012-01-25 |
2017-07-10 |
Вертекс Фармасьютікалз Інкорпорейтед |
СКЛАД 3-(6-(1-(2,2-ДИФТОРОБЕНЗО[d][1,3]ДІОКСОЛ-5-ІЛ)ЦИКЛОПРОПАНКАРБОКСАМІДО)-3-МЕТИЛПІРИДИН-2-ІЛ)БЕНЗОЙНОЇ КИСЛОТИ
|
BR112014021090B1
(pt)
|
2012-02-27 |
2023-01-24 |
Vertex Pharmaceuticals Incorporated |
Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma
|
EP2838882A1
(en)
|
2012-04-20 |
2015-02-25 |
Vertex Pharmaceuticals Incorporated |
Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
GB201207406D0
(en)
|
2012-04-27 |
2012-06-13 |
Glaxo Group Ltd |
Novel compounds
|
CA2874851A1
(en)
|
2012-06-08 |
2013-12-12 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions for the treatment of cftr-mediated disorders
|
AU2013290444B2
(en)
|
2012-07-16 |
2018-04-26 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
|
NZ745659A
(en)
|
2012-11-02 |
2020-04-24 |
Vertex Pharma |
Pharmaceutical compositions for the treatment of cftr mediated diseases
|
MY178621A
(en)
|
2012-11-19 |
2020-10-19 |
Vertex Pharmaceuticals Europe Ltd |
Deuterated cftr potentiators
|
WO2015051043A1
(en)
|
2013-10-01 |
2015-04-09 |
Amgen Inc. |
Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
|
JP6963896B2
(ja)
|
2013-11-12 |
2021-11-10 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Cftr媒介性疾患の処置のための医薬組成物を調製する方法
|
PT3925607T
(pt)
|
2014-04-15 |
2023-09-26 |
Vertex Pharma |
Composições farmacêuticas para o tratamento de doenças mediadas pelo regulador de condutância transmembranar da fibrose quística
|
TW202140422A
(zh)
|
2014-10-06 |
2021-11-01 |
美商維泰克斯製藥公司 |
囊腫纖維化症跨膜傳導調節蛋白之調節劑
|
KR20170063954A
(ko)
|
2014-10-07 |
2017-06-08 |
버텍스 파마슈티칼스 인코포레이티드 |
낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
|
RU2691136C2
(ru)
|
2014-11-18 |
2019-06-11 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии
|
WO2016121399A1
(ja)
|
2015-01-29 |
2016-08-04 |
京セラ株式会社 |
測定装置およびセンサシステム
|
WO2016160945A1
(en)
|
2015-03-31 |
2016-10-06 |
Concert Pharmaceuticals, Inc. |
Deuterated vx-661
|
US9840513B2
(en)
|
2015-07-16 |
2017-12-12 |
Abbvie S.Á.R.L. |
Substituted tricyclics and method of use
|
MX2018003331A
(es)
|
2015-09-21 |
2018-08-16 |
Vertex Pharmaceuticals Europe Ltd |
Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados.
|
EP3436432B1
(en)
|
2016-03-30 |
2021-01-27 |
Genentech, Inc. |
Substituted benzamides and methods of use thereof
|
CA3019380A1
(en)
|
2016-03-31 |
2017-10-05 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
KR102448404B1
(ko)
|
2016-04-07 |
2022-09-27 |
프로테오스타시스 테라퓨틱스, 인크. |
규소 원자 함유 이바카프터 유사체
|
CA3016303A1
(en)
|
2016-04-26 |
2017-11-02 |
Abbvie S.A.R.L. |
Modulators of cystic fibrosis transmembrane conductance regulator protein
|
US10138227B2
(en)
|
2016-06-03 |
2018-11-27 |
Abbvie S.Á.R.L. |
Heteroaryl substituted pyridines and methods of use
|
US10899751B2
(en)
|
2016-06-21 |
2021-01-26 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing CFTR activity
|
US20180012171A1
(en)
|
2016-07-05 |
2018-01-11 |
Elie Massabki |
On-demand resource allocation
|
CN109803962B
(zh)
*
|
2016-09-30 |
2022-04-29 |
弗特克斯药品有限公司 |
囊性纤维化跨膜传导调控蛋白的调节剂、以及药物组合物
|
US10399940B2
(en)
|
2016-10-07 |
2019-09-03 |
Abbvie S.Á.R.L. |
Substituted pyrrolidines and methods of use
|
US9981910B2
(en)
|
2016-10-07 |
2018-05-29 |
Abbvie S.Á.R.L. |
Substituted pyrrolidines and methods of use
|
AU2017348183A1
(en)
|
2016-10-26 |
2019-05-16 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for modulating CFTR
|
CA3041676A1
(en)
|
2016-10-26 |
2018-05-03 |
Daniel Parks |
Pyridazine derivatives, compositions and methods for modulating cftr
|
US20190256474A1
(en)
|
2016-10-26 |
2019-08-22 |
Proteostasis Therapeutics, Inc. |
N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
|
WO2018080591A1
(en)
|
2016-10-27 |
2018-05-03 |
Vertex Pharmaceuticals (Europe) Limited |
Methods of treatment with deuterated cftr potentiators
|
EP3541390B1
(en)
|
2016-11-18 |
2024-05-01 |
Cystic Fibrosis Foundation |
Pyrrolopyrimidines as cftr potentiators
|
HUE052205T2
(hu)
|
2016-12-09 |
2021-04-28 |
Vertex Pharma |
Cisztás fibrózis transzmembrán vezetõképesség szabályzó modulátora, gyógyszerészeti készítmények, kezelési eljárások és eljárás a modulátor elõállítására
|
EP3554506B1
(en)
|
2016-12-16 |
2021-04-28 |
Cystic Fibrosis Foundation |
Bycyclic heteroaryl derivatives as cftr potentiators
|
WO2018116185A1
(en)
|
2016-12-20 |
2018-06-28 |
AbbVie S.à.r.l. |
Deuterated cftr modulators and methods of use
|
EP3565815B1
(en)
|
2017-01-07 |
2024-03-13 |
Fochon Pharmaceuticals, Ltd. |
Compounds as bcl-2-selective apoptosis-inducing agents
|
TW201831471A
(zh)
|
2017-02-24 |
2018-09-01 |
盧森堡商艾伯維公司 |
囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
|
US20180280349A1
(en)
|
2017-03-28 |
2018-10-04 |
Vertex Pharmaceuticals Incorporated |
Methods of treating cystic fibrosis in patients with residual function mutations
|
MA48994A
(fr)
|
2017-03-30 |
2020-02-05 |
Hoffmann La Roche |
Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
|
EP3615528B1
(en)
|
2017-04-28 |
2022-02-16 |
Proteostasis Therapeutics, Inc. |
4-sulfonylaminocarbonylquinoline derivatives for increasing cftr activity
|
US11253509B2
(en)
|
2017-06-08 |
2022-02-22 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
WO2019010092A1
(en)
|
2017-07-01 |
2019-01-10 |
Vertex Pharmaceuticals Incorporated |
COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS
|
TW201920081A
(zh)
|
2017-07-11 |
2019-06-01 |
美商維泰克斯製藥公司 |
作為鈉通道調節劑的羧醯胺
|
BR112020000941A2
(pt)
|
2017-07-17 |
2020-07-21 |
Vertex Pharmaceuticals Incorporated |
métodos de tratamento para fibrose cística
|
WO2019018353A1
(en)
|
2017-07-17 |
2019-01-24 |
Vertex Pharmaceuticals Incorporated |
METHODS OF TREATING CYSTIC FIBROSIS
|
US11434201B2
(en)
|
2017-08-02 |
2022-09-06 |
Vertex Pharmaceuticals Incorporated |
Processes for preparing pyrrolidine compounds
|
US10988454B2
(en)
|
2017-09-14 |
2021-04-27 |
Abbvie Overseas S.À.R.L. |
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
|
CA3078230A1
(en)
|
2017-10-06 |
2019-04-11 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions and methods for increasing cftr activity
|
WO2019079760A1
(en)
|
2017-10-19 |
2019-04-25 |
Vertex Pharmaceuticals Incorporated |
CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS
|
WO2019113089A1
(en)
|
2017-12-04 |
2019-06-13 |
Vertex Pharmaceuticals Incorporated |
Compositions for treating cystic fibrosis
|
WO2019113476A2
(en)
|
2017-12-08 |
2019-06-13 |
Vertex Pharmaceuticals Incorporated |
Processes for making modulators of cystic fibrosis transmembrane conductance regulator
|
TWI810243B
(zh)
|
2018-02-05 |
2023-08-01 |
美商維泰克斯製藥公司 |
用於治療囊腫纖化症之醫藥組合物
|
MX2020008268A
(es)
|
2018-02-15 |
2020-09-21 |
Vertex Pharma |
Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quistica, composiciones farmaceuticas de estos, su uso en el tratamiento de la fibrosis quistica y procesos para elaborarlos.
|
WO2019191620A1
(en)
|
2018-03-30 |
2019-10-03 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms of modulators of cftr
|
WO2019195739A1
(en)
|
2018-04-05 |
2019-10-10 |
Alexander Russell Abela |
Modulators of cystic fibrosis transmembrane conductance regulator
|
US11414439B2
(en)
|
2018-04-13 |
2022-08-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
|
MA54227B1
(fr)
|
2018-11-14 |
2023-03-31 |
Vertex Pharma |
Méthodes de traitement de la fibrose kystique
|
CA3119656A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Macrocyclic compounds and their use in the treatment of disease
|
US20220127247A1
(en)
|
2019-02-06 |
2022-04-28 |
Novartis Ag |
N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
|
WO2020191227A1
(en)
|
2019-03-20 |
2020-09-24 |
Cornell University |
Methods for controlling prostaglandin-mediated biological processes
|
TW202102482A
(zh)
|
2019-04-03 |
2021-01-16 |
美商維泰克斯製藥公司 |
囊腫纖維化跨膜傳導調節蛋白調節劑
|
WO2020214921A1
(en)
|
2019-04-17 |
2020-10-22 |
Vertex Pharmaceuticals Incorporated |
Solid forms of modulators of cftr
|
WO2020242935A1
(en)
|
2019-05-29 |
2020-12-03 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
TW202120517A
(zh)
|
2019-08-14 |
2021-06-01 |
美商維泰克斯製藥公司 |
製備cftr調節劑之方法
|
CN114585628B
(zh)
|
2019-08-14 |
2024-03-26 |
弗特克斯药品有限公司 |
囊性纤维化跨膜传导调节因子的调节剂
|
BR112022002605A2
(pt)
|
2019-08-14 |
2022-05-03 |
Vertex Pharma |
Formas cristalinas de moduladores de cftr
|
TW202115092A
(zh)
|
2019-08-14 |
2021-04-16 |
美商維泰克斯製藥公司 |
囊腫纖維化跨膜傳導調節蛋白之調節劑
|
MX2022005810A
(es)
|
2019-11-12 |
2022-06-08 |
Genzyme Corp |
Heteroarilaminosulfonamidas de 6 miembros para tratar enfermedades y afecciones mediadas por la actividad de regulador de la conductancia transmembrana de la fibrosis quistica (cftr) deficiente.
|
AU2020384279A1
(en)
|
2019-11-12 |
2022-05-26 |
Genzyme Corporation |
5-membered heteroarylaminosulfonamides for treating conditions mediated by deficient CFTR activity
|
CR20230120A
(es)
|
2020-08-07 |
2023-09-01 |
Vertex Pharma |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
CN116322676A
(zh)
|
2020-08-13 |
2023-06-23 |
弗特克斯药品有限公司 |
Cftr调节剂的结晶形式
|